<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 175 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page174.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=175">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 175 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 175</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=175"><img src="../thumb/175.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>142 / 2020-04                                                        Blood and Haemopoeitic - 8.4
   long.than usual to stop & to advise other medic.practit.accord., pts.  incr.GI bleed. risk with anti-platelet agents/SSRI’s & corticoster.,   MYOPRIN 100 mg, (Biotech) iPharma. [P/S]
   at incr.risk of bleed.from les.with propens to bleed esp. GI & intra-  dimin.eff.of anti-gout preps., barbit. & other sedat. enhanc.aspir.  Aspirin
   ocul./trauma/surg.or other patholog. condits., caref.monit.for bleed.  toxicity & poss.mask resp.sympt.  Indications: Reduc.MI risk in pts.with unstab. angina/pts.who have
   incl.occult esp.but not limit.to dur.1  wk.of treatm.&/aft.card. pro-  Warnings: Reye’s syndr.  had prev.MI, reduc.risk of recurr.trans.ischaem.attacks/stroke in men
                  st
   ced./ surg., mod.hepat.dis., ren.impairm., cont. hydrogenat.castor   who have had trans.brain ischaem.due to fibrin.platelet emboli, reduc.
   oil, cons.bld.cell count &/other appropr. test.in case of clinic.bleed.  ECOTRIN, Litha [P/S]  risk of graft occlus.follow.aorta coron.by-pass surg.
                                Aspirin.
   sympt. dur. ther., rare heredit.galact.intol.probl., Lapp lact.defic.,   (S2) TABS. B/2.7/1117
   gluc.-galact.malabsorpt.     Indications: Reduc.MI risk in pts.with unstable angina/ pts.who   721258-001: 100 mg, 30, R28,44
                                have had prev.MI, reduc.risk of recurr.trans.ischaem.attacks/stroke
   Drug interactions: Poss.pharmacodynam. interact. betw.clopidog-  Dosage: Do not exceed recomm.dly.dos.
   rel & glycoprot. IIb/ IIIa inhibit., reduc.eff.with concom.meds.inhib.   in men who have had trans.brain ischaem.due to fibrin.platelet em-  Adults: 100 mg dly.pref.at same time dly.with meals.
                                boli, to reduc.risk of graft occlus.follow.aorta coron. by-pass surg.
   CYP2C19 activ., act.of one of the Cytochrome P 450 (CYP) enzym.(CYP   (S2) EC TABS, 29/2.7/0767  Contraindications: Haemorrhag.disords., gout, aspir.intol.esp.
                                                                        st
   2C9)poss.inhib., poss.incr. plasma lev.of phenytoin/tolbutamide (data   823481-018: 81 mg, 50, R63,11  aspirin.-sens.asthmat., 1  & 3rd trimest.of pregn.
   indic. phenytoin & tolbutamide can be safely co-admin.)/ torsemide /  823481-026: 81 mg, 100, R126,22  Side effects: Dizzin., eros., ulcerat., heamatemes., melaena, hypers-
   tamoxifen/fluvastatin/NSAID metabol. by CYP 2C9, eff.of acetylsalic.  Dosage: Adults: 1-3 tabs.dly, pref.at same time dly.only on Drs   ens.reacts., angio-edema, rhinit., paroxysmal bronchosp., dyspn., incr.
   acid on collag.induc. platelet aggregat.potent.  advice    bleed.time, hypoprothrombinaem.in large dos., GI disturbs., hepato-
   CLOPIWIN PLUS 75/75, Zentiva [P/S]  Contraindications: Haemorrhag.disords., gout, aspirin sens.incl.  tox.partic.in juvenile arthrit.& other connect.tiss.disords.
                                                              Special precautions: Optim.inhibit.of platelet aggregat. dos.not
   Clopidogrel 75mg, acetylsalicylic acid 75 mg.  aspirin sens.asthmat., 1st & 3rd trimest.pregn., lactat.  known, use only as direct.by Dr., imp. ren./hepat.funct., discont.1wk.
   Indications: Reduct.of atherosclerot.events in adults already tak-  Side effects: Dizz., GI-irrit./-ulcerat., N&V, haematemes., melaena,   bef.surg. proced., implic.in Reye’s syndr.partic.in childr.& adolesc.
   ing both clopidogrel & acetylsalicyl.acid in ac.coron.syndr.pts.with   hypersens.reacts.incl.skin erupt./ angio-oed./rhinit./paroxysm.bron-  with chickenpox & flu theref.consult Dr, dyspeps., anaem., dehydrat.
   non-ST-segm.elevat.ac.coron.syndr.(unstab.ang./non-Q-wave MI)  chosp.& dyspn., incr.bleed.time., hypoprothrombinaem.  Drug interactions: Effs.of coumar.anticoags./ sulphonylur./ hy-
   incl.medic.manag.pts./those to be manag. with percut.coron.inter-  Warnings and special precautions: Reye’s syndr., imp.hepat./  poglycaem.agents/methotrex/ phenytoin & valproic acid enhanc.,
   vent.with/without stent or CABG & in pts.with ST-segm.elev.ac.MI.  ren. funct., dyspeps., anaem., dehydrat., withdr.1 wk. bef. surg.,   probenec.& sulphinpyrazone effs.diminish.
   (S3) TABS, 44/8.2/0657       asthmat., poss. hepatotoxic.partic.with juven.arthrit.& other con-
   720916-001: 28, R208,46      nect. tiss.disords.           PERSANTIN, Ing.Pharm [P/S]
   720916-002: 30, R223,25      Interactions: Enhanc.act.of coumarin anticoag./ sulphonylurea,/  Dipyridamole.
   Dosage: One tab as sngl.dly.dos. follow.init.load. dos. of clopidog-  hypoglycaem.agents/methotrex./ phenytoin & valproic acid, dimin.  Indications: Thallium scann.exerc.stress substit. in myocard.per-
   rel in combin.with ASA.      eff.of uricosuric agents      fus.imag.for eval.coron.artery dis. where pts.cannot exerc.adeq.
   In ST segm.elev.ac.MI init.ther.as soon as poss. aft.sympt.start &   INTEGRILIN, MSD [P/S]  (S3) AMPS. H535. 10 mg/2 mL.
   contin.for at least 4 wks. Init. ther.without clopidogrel load.dos.  Eptifibatide  798746-009: 5 amps, R477,21
   in pts.&gt;75 yrs.              Indications: Used concom.with aspir.& unfractionat. hepar.to reduc.  Dosage: Indiv. Infus.0,142 mg/kg/min (0,57 mg/kg total) IV over 4
   Contraindications: Act./bleed.hist., safety & effic. in childr.&lt;18   risk of death/MI in pts. pres. with unstable angina/non-Q-wave MI   mins. Addit.0,27 mg/kg may be infus. over an addit. 6 mins. Tot.dos.of
   yrs./pregn.& lactat.not est., sev. hepat.insuffic., thrombocytopen.,   in pts. manag.with std.medic.ther.and/or percutan. coron. intervent.,   0,84 mg/kg not to be exceed. Dil. to 1:2 ratio with NaCl 0,45 %/0,9 %
   platel.dysfunct., NSAID allerg., asthma, rhinit., nasal polyp, sev.   adjunct.to percutan.translumin. coron. artery intervent.for prev.of   or gluc. 5 % to tot.vol.20-50 mL. Inj. thallium within 5 mins.
   ren. impairm., HF, prev.NSAIDs GI relat.bleed. hist./ ulcer./perforat.  abrupt clos.of treat. coron.vessel & relat.ac.ischaem.card. complicat.  Contraindications: Pref.not in hypotens.pts.but if deem.necess.
   Side effects: Thrombot.thrombocytopen.purpura (TTP), fluid retent.,   (S4) INJ. 31/8.2/0539, 0540.  admin.very slowly, haemodynam. instabil.follow.MI.shock & col-
   oed., HF, bleed.time prolong., skin reacts.incl.Stev.Johns.syndr./tox.  843539-003: 0,75 mg/ml, 1x 100 ml vial, R3 191,13  lapse, usual exer. test.C/I, safety in pregn.& lactat.not est., safety &
   epiderm. necrolys./exfol.dermatit./lichen planus, bleed. somet. fatal   843520-019: 2 mg/ml, 1x10 ml vial, R851,03  effectiven.in childr.not est.
   esp.GI/retroperiton./arter.punct.site/ skin/eye/musculoskelet./resp.  Dosage: Used concom.with aspirin & unfract. hepar. unless con-  Side effects: Hypersens.reacts.incl.anaphylax.& bronchosp., head-
   tract, leucopen., eosinophil., neutropen., aplast.anaem., IC bleed.,   tra-indicat.  ache, dizzin., paraesthes., syncope, arrythm., chest pain, ang.pect.,
   headache, dizzin., paraesthes., vertigo, haematoma, epistax., GI   Adults old.than 18 yrs:   MI, card. death/arrest, sev.hypotens., hot flush., cerebrovasc. events,
   disturbs.incl.exacerbat. colit./ Chron’s dis., haematur., anaphylact.  Unstable ang./non-Q-wave MI:  seiz., GI disturbs., myalgia, ECG chang., oed.
   reacts., ser. sickn., psych./CNS/hepato-bil.disords., vasculit., hyper-/  Creatinine clear.&gt; 50 ml/min: Recomm.dos: IV bolus of 180 mcg/  Warnings and special precautions: Do not mix. with other drugs,
   hypotens., bronchosp., interstit. pneumonit., stomatit., pancreatit.,   kg as soon as poss.follow. diagn., immed.follow.by contin.infus.of   disc.xanthine derivats.24 hrs.bef. admin., disc.oral dipyridamole
   ac.liv.fail., hepatit., arthrit., arthralg., myalg., glomerulonephrit., fev.,   2,0 mcg/kg /min. for up to 72 hrs.until coron.artery bypass graft surg./  ther.24 hrs.prior to IV stress test., S/E more freq.& sev.with high dos.
   infect., anaphylax., allerg. sympt. aggravat., hypoglycaem., gout, hear.  discharge whichever first. If PTCA perform. dur. ther.cont.infus.for 20-  IV use, eval. benef.-risk ratio of IV use, appropr. monit. advis., pts.with
   loss, tinnit., operat.wound haemorrh.  24 hrs.post-PTCA for overall max.durat.of 96 hrs.  asthma/sev.coron.heart dis. hist. at incr.risk, parenter.aminophylline
   Warnings and special precautions: Pts.to be advis.of TTP S&S,   Creatinine clear.&lt; 50 ml/min: Recomm.dos: IV bolus of 180 mcg/  to be readily avail.for bronchosp.& chest pain, consid. MI if chest
   recent TIA/stroke/those at high risk of recurr.ischaem.events, hy-  kg as soon as poss.follow. diagn., immed.follow.by contin.infus.of   pain not reliev.by aminophyllin.& nitroglycer. admin., myasthen.grav.
   pertens.&/ HF hist., elderly, asthma/allerg.disord.hist., gout, Reye’s   1,0 mcg/kg/ min.for up to 72 hrs.until coron.artery bypass graft surg./  Interactions: Xanthine derivat.may weaken eff., incr.adenosine
   syndr., bleed.tendenc.esp.GI/intraocul., pts.to be aware bleed.may   discharge whichever first. If PTCA perform. dur. ther.cont.infus.for 20-  plasma lev.& CV effs., may incr. hypotens.eff.of BP lower.drugs, may
   take long.to stop & to advise medic.practit./dentist accord., mild to   24 hrs. post-PTCA for overall max.durat.of 96 hrs.  counteract. anticholinesterase eff.of cholinesterase inhibit.
   mod. hepat./ ren.impairm., cont.hydrogenat.castor oil, ASA excret.in   Percutan.coron.intervent:
   human milk, poss.myelotoxic., discont. 7 days bef.elect.surg., spin./  Creatinine clear.&gt; 50 ml/min:  PHARMA DYNAMICS CLOPIDOGREL 75 mg, Pharma
   epidur. anaesth./ lumb.punct.dur.treatm./7 days theraft., incr. bleed.  Recomm. dos: IV bolus 180 mcg/kg immed.prior to proced.follow.by   Dynamics [P/S]
   risk from trauma/surg./other pathalog. condits.assoc.with bleed.  2  bolus 180 mcg/kg 10 mins.aft. 1  bolus. Simultan.with 1  bolus init.  Clopidogrel bisulfate
                                                        st
                                              st
                                 nd
   diasthes.& concom. NSAID’s /heparin/glycoprot.IIb/IIIa inhibit./   contin.infus. at 2,0 mcg/kg/min. Contin.infus.until hospit. discharge/   Indications: Reduct.of atherosclerot.events in pts. with hist.of symp-
                           st
   thrombolyt., caref.monit.for bleed.esp.but not limit. to dur.1  wks.of   max.18-24 hrs.post PCI. Min.of 12 hrs of infus.recomm.  tomat.atherosclerot.dis. defin.by ischaem.stroke from 7 days until &lt;6
   treatm.&/aft.invas.card.proced./ surg., discont.ther.if GI bleed./per-  Creatinine clear.&lt; 50 ml/min:  mnths, MI from a few days until &lt;35 days or est. periph.arter.dis.
   forat./ulcer./ occurs/ when rash appears/mucos.les.& hypersens., GI   Recomm. dos: IV bolus 180 mcg/kg immed.prior to proced. follow.by   (S3) TABS, A42/8.2/0128
   dis.hist./pept.ulc./GI haemorrh./ min. upp.GI sympt., concom.throm-  2  bolus 180 mcg/kg 10 mins.aft. 1  bolus. Simultan.with 1  bolus init.  714293-001: 75 mg, 30, R176,40
                                              st
                                 nd
                                                        st
   bolyt.agents/ proton pump inhibit., concom.strong/mod. CYP2C19   contin.infus. at 1,0 mcg/kg/min. Contin.infus.until hospit. discharge/   Dosage: 75 mg as sngl.dly.dos.
   inhibits./oral anticoags.not recomm., lact.intol.  max.18-24 hrs.post PCI. Min.of 12 hrs of infus.recomm.  Contraindications: Act.bleed., safety & effic.in childr.&lt;18 yrs.
   Drug interactions: Incr.GI bleed.risk with SSRI’s, incr.PUBs risk with   Contraindications: Clinic.signific.GI/GU bleed./ other act.abnorm.  not est., pregn. & lactat., sev.liv. impairm., thrombocytopen., pla-
   corticoster., methotrexate ren.clear.inhib.at dos.&gt; 20 mg/wk, poss.in-  bleed.within 30 days, stroke within 30 days/haemorrhag. stroke hist.,   tel. dysfunct.
   teract. with heparin, ibuprofen poss. inhib.aspir.eff., eff.of uricosur.  CVA hist., CNS struct.abnormalit.(e.g.intracran.neoplasm, arterioven.   Side effects: Thrombot.thrombocytopen. purpura (TTP), purpura,
   agents poss.inhib.by ASA, incr.eff.with concom.NSAIDs, reduc.eff.  malformat./aneurysm), maj.surg./ trauma within past 6 wks., bleed.  haematoma, epistax., sev. neutropen.& thrombocytopen., aplast.
   with meds.inhib. CYP2C19 activ., poss.incr.plasma lev.of cert.meds.   diathes.hist., thrombocytopen. (&lt;100 000 cells/mm ), developm. of   anaem., bruis., haematur., ocul./resp.tract./ musculoskelet. bleed.,
                                                      3
   metabol.by CYP 2C9 e.g.phenytoin/tamoxifen/ torsemide.  ac.profound thrombocytopen.with prev. eptifibatide treatm., pro-  haemorrhag.ulc., haemothorax, operat.wound haemorrh., retroperi-
                                thromb.time &gt;1,2 times control/ INR&gt;2,0, haematocrit &lt;30%, clinic.   ton. haemorrh., GI disturbs., skin reacts. incl. erythem multiforme/
   DISPRIN CARDIOCARE, Reckitt Benckiser [P/S]  signific. hepat.impairm., sev. ren.fail.(creatinine clear.&lt;30 ml/min),   Stev.Johns.syndr.& tox. epiderm. necrolys., CNS effs., hallucinat.,
   Aspirin                      ren.dialys.depend., sev. hypertens. (systol.BP &gt;200 mm Hg/diastol.BP   taste disords., chest pain, atrial fibrillat., palpitat., oed., hyper-/hypo-
   Indications: Reduc.MI risk in pts.with unstab. ang./ pts.who have   &gt;110 mm Hg on antihypertens.ther.), concom./plan. admin. of another   tens., vasculit., URTI, rhinit., interstit. pneumonit., abnorm.liv.funct.
   had prev.MI, reduc.risk of recurr.trans.ischaem.attacks/stroke in men   parenter.GP IIb/IIIa inhibit., safety in pregn./lactat.& childr.not est.  tests, hepatit., ac.liv.fail., UTI, arthralg., back pain, gout, leg cramps,
   who have had trans.brain ischaem.due to fibrin.platel. emboli, reduc.  Side effects: Min.& maj.bleed.events.incl.very rare fatalit., need.for   myalg., arthrit., gen.pain, flu-like sympts., fatig., asthen., tooth dis-
   risk of graft occlus.follow.aorta coron.by-pass surg.  bld.transfus.modestly incr., hypotens., atrial fibrillat., CHF, card.arrest,   ord., hypersens. reacts.
   (S0) CARDIOCARE DISPERS.TABS.31/2.8/0071  shock, prolong. bleed.time,  AV block, phlebit., ventric. fibrillat./-tach-  Special precautions: Pts.to be advis.of TTP S&S, discont.if TTP
   847283-003: 100 mg, 30, R43,64  ycard., thrombocytopen., cerebr. ischaem., back pain, inj. site reacts.,   suspect., pts.at incr.risk of bleed. from dent./surg.proced./or other
   847283-004: 100 mg, 60, R83,49  anaphylax., rash, urticar., pulm haemorrh.  condits./ disords. requir.concom.glycoprot.IIb/IIIa inhibit., concom.
   Dosage: 100-300 mg dly, pref.at same time each day.  Warnings and special precautions: Concom. meds. affect.   meds.that incr.bleed.risk, safety of concom. acetylsalicyl.acid/hepa-
   Contraindications: Pept.ulc., haemophil., sev. ren. impairm., oral   haemostas., do not mix.with drugs that have not been found to be   rin/thrombolyt.& warfar. not est., concom.NSAID’s incl.COX-2 inhibit.,
   anticoag., 1st & 3rd trimest. pregn.& lactat., GI bleed/perforat.relat.  compatible, termin. infus. immed.if emerg./urgent card.surg.reqd.&   caref.monit.for bleed.esp.dur.1  wk.of treatm. & aft.invas.card.pro-
                                                                           st
   to prev. NSAID’s, act./hist.of recurr.ulc./haemorrh or perforat., HF  in the case of semi-elect.surg.discont.infus.to allow platelet funct.to   ced./surg., discont.7 days prior to surg.if antiplatel.eff.not desir., les.
   Side effects: GI-irrit./eros.result.dyspeps., ulcerat., haematemes.&   return to norm., pts.weigh.&lt;74 kg at incr.risk of bleed., discont.infus.&   with propens.to bleed.eg.GI ulc., pts.to be aware that bleed.may take
   malaena, N&V, abdom. pain, diarrh., flatul., constip., ulcerat.stomatit.,   concom. hepar. immed. if ser.bleed.not control.with press., see lit.   long.than usual to stop & to advise medic.practit.accord., where pts.
   Crohn’s dis & colit.exacerbat., gastrit., dizzin., incr. bleed.time, bld.  for recomm.bleed.precaut.regard.the arterial access site & femoral   at high risk of recurr.ischaem.events combinat.with aspir. not prov.
   dyscras.& Fe defic.anaem. with prolong.high dos, ren.papill.necros.,   sheath insert., see lit. for gen.nurs.guidelines, observ.all potent.bleed.   to be more effect.but shown to incr. maj.bleed., do not init.treatm.
   oed., hypertens., CF, hypersens.reacts.incl.paroxysm. bronchosp. &   sites caref., monit.platelet count/ext.of hepar. anticoag. dur./follow.  within 1  few days follow.MI, not recomm.in CABG & ac. ischaem.
                                                                 st
   dyspn./bullous reacts.incl.Stev. John. syndr.& tox.epiderm.necrolys.  treatm., monit.ACT & maint. target value if coron.angioplasty/non-  stroke(&lt;7 days), ren.impairm., mod. hepat. dis.with bleed.diathes.
   Special precautions: Hypertens.hist/HF due to poss.fluid retent./  urg.coron. angioplasty with intracoron.stent.is to be perform., monit.   Drug interactions: Eff.of acetylsalic.acid on collag. induc.platelet
   oed., incr.freq.of NSAID advers. reacts.esp.GI bleed./perforat.in el-  pt.for poss.thrombocytopen.assoc. hypersens. signs incl.hypotens.,   aggregat.potent., potent.GI bleed. risk with NSAID’s, incr.lev.of drugs
                                                   3
   derly, GI bleed./ perforat.risk incr.with high.dos.in ulc. hist. & elderly,   if confirm.platelet count &lt;100 000 cells/mm /profound. thrombocy-  metabol. by CYP2C9 enzyme.
   GI dis.hist., discont.at 1  sign of hypersens./ GI bleed.or ulcerat., with-  topen. observ.discont.immed.& instit. treatm., hepat.impairm.where
            st
   dr.1 wk.bef. surg. because of poss. incr.bleed.time, allerg. reacts.more   coagulat.could be affect., mod.to sev.ren.insuff., no exper.with con-  PLAGROL, Adcock Ingram Ltd [P/S]
   common in asthmat., imp.ren.funct., dyspeps., anaem., dehydrat.  com. low molecul.weight hepar.  Clopidogrel
   Drug interactions: Other GI irrit.eg NSAID’s incr. S/E, act.of cou-  Interactions: Incr.bleed.risk when admin.with streptokinase in ac.MI   Indications: Reduct.of atherosclerot.events in pts. with hist.of
   marin anticoags./methotrex./ oral antidiabet.& sulphonam.enhanc.,   study, incompat.with furosemide.  symptomat.atherosclerot.dis. defin. by ischaem.stroke (from 7 days</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page174.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page170.html">170</a>&nbsp;&nbsp;&nbsp;<a href="page171.html">171</a>&nbsp;&nbsp;&nbsp;<a href="page172.html">172</a>&nbsp;&nbsp;&nbsp;<a href="page173.html">173</a>&nbsp;&nbsp;&nbsp;<a href="page174.html">174</a>&nbsp;&nbsp;&nbsp;<a href="page175.html">175</a>&nbsp;&nbsp;&nbsp;<a href="page176.html">176</a>&nbsp;&nbsp;&nbsp;<a href="page177.html">177</a>&nbsp;&nbsp;&nbsp;<a href="page178.html">178</a>&nbsp;&nbsp;&nbsp;<a href="page179.html">179</a>&nbsp;&nbsp;&nbsp;<a href="page180.html">180</a>
             </td>
             <td width="35%"><a href="page176.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page176.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
